Emergent BioSolutions Inc.
EBS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EBS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EBS
Emergent BioSolutions Inc. is a public health company focused on medical countermeasures and NARCAN® Nasal Spray, with a portfolio of 11 products and a development pipeline addressing chemical, biological, radiological, nuclear, and emerging infectious disease threats.
Key risk: High debt leverage
BioSniper Score
Based on 6 of 6 signals
Market Cap
$303.0M
Cash Runway
—
Lead Asset
anthrasil (Approved)
Next Catalyst
Patent_Expiry · Oct 10, 2034Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 14 clinical trials · 1 catalyst for Emergent BioSolutions Inc..
Emergent BioSolutions Inc. is a public health company focused on medical countermeasures and NARCAN® Nasal Spray, with a portfolio of 11 products and a development pipeline addressing chemical, biological, radiological, nuclear, and emerging infectious disease threats.
- As of June 30, 2026, Emergent had cash and equivalents of $140.9M, total revenue of $234.3M, net income of -$180.2M, shareholders' equity of $536.2M, and total debt of $589.7M [sec].
- The company has a product portfolio of 11 products, 10 of which are owned, and a development pipeline of pre-clinical and clinical stage candidates [sec_mda · as of 2026-02-27].
- Emergent has achieved ~$250M in cost structure optimization savings since January 2023 and $130M in annualized savings announced in 2024 [sec · filed 2025-03-21].
- The company refinanced and extended debt maturity to 2029, entered a $250M Term Loan with Oak Hill Advisors, and closed a $100M ABL revolver led by Wells Fargo [sec · filed 2025-03-21].
- Net cash used in investing activities for the six months ended June 30, 2026 increased $131.4M, driven by a $50.4M milestone payment related to Ebanga® development [sec_mda · as of 2026-08-06].
What works
- Emergent has a diversified portfolio of 11 products (10 owned) addressing multiple public health threat categories, providing revenue stability from government and commercial customers [sec_mda · as of 2026-02-27].
- The company has significantly improved profitability, with adjusted EBITDA of $183.1M in 2024 compared to $(22.3)M in 2023 [sec · filed 2025-03-21].
- Cost structure optimization savings of ~$250M since January 2023 and $130M in annualized savings announced in 2024 demonstrate operational efficiency gains [sec · filed 2025-03-21].
- Debt refinancing extended maturities to 2029 and provided access to a $250M Term Loan and $100M ABL revolver, enhancing financial flexibility [sec · filed 2025-03-21].
What to weigh
- The company reported a net loss of $180.2M for the six months ended June 30, 2026, indicating ongoing profitability challenges [sec].
- Total debt of $589.7M as of June 30, 2026, exceeds shareholders' equity of $536.2M, reflecting a leveraged balance sheet [sec].
- Cash used in investing activities increased by $131.4M in the first half of 2026, partly due to a $50.4M milestone payment for Ebanga® development, straining cash resources [sec_mda · as of 2026-08-06].
- The company may seek additional external financing, and future capital requirements depend on uncertain factors including product sales, development costs, and debt obligations [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Emergent has a portfolio of 11 products, 10 owned, and a development pipeline.
“We have a product portfolio of 11 products, 10 of which are owned by the Company, that contribute a substantial portion of our revenue and are sold to government and commercial customers. Additionally, we have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates.”
SEC MD&A · February 27, 2026
The company achieved significant cost savings and improved profitability.
“~$250M of cost structure optimization savings since January 2023 • $130M of annualized savings announced in 2024”
SEC filings · March 21, 2025
Emergent refinanced debt and secured new credit facilities.
“Reduced net debt, refinanced and extended debt maturity to 2029 • Entered into $250M Term Loan with Oak Hill Advisors • Closed $100M ABL revolver led by Wells Fargo”
SEC filings · March 21, 2025
The company may need additional external financing.
“We may seek additional external financing to provide additional financial flexibility.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2034-10-10 · Patent_Expiry · TEMBEXA — Patent/Exclusivity Expiry: TEMBEXA — The patent expiry for TEMBEXA could affect future revenue from this product, though the date is distant.
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $589.7M exceeds equity of $536.2M as of June 30, 2026, increasing financial risk [sec].
- Net loss trend — Net loss of $180.2M for six months ended June 30, 2026, indicates ongoing unprofitability [sec].
- Cash burn from investing — Investing cash outflow increased $131.4M in H1 2026, partly due to a $50.4M milestone payment for Ebanga® [sec_mda · as of 2026-08-06].
- Dependence on external financing — Company may seek additional external financing, with future capital needs uncertain [sec_mda · as of 2026-08-06].
What to watch
- Monitor the company's ability to achieve sustained profitability given the net loss of $180.2M as of June 30, 2026 [sec].
- Track debt management and refinancing progress, with total debt of $589.7M and extended maturity to 2029 [sec].
- Watch for updates on Ebanga® development and related milestone payments, which impacted cash flow in H1 2026 [sec_mda · as of 2026-08-06].
- Observe any potential asset sales or additional financing moves as indicated in risk disclosures [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Emergent BioSolutions Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Emergent BioSolutions Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 2.27 · 0% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~2963d
0 buys · 9 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
190
Total value held
$358.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,515,990 | $37.5M |
| blackrock, inc. | 4,341,462 | $36.0M |
| state street corp | 2,849,701 | $23.7M |
| dimensional fund advisors lp | 2,757,158 | $22.9M |
| american century companies inc | 2,425,722 | $20.1M |
| charles schwab investment management inc | 1,506,075 | $12.5M |
| geode capital management, llc | 1,272,909 | $10.6M |
| palisade capital management, lp | 1,201,323 | $10.0M |
| vanguard portfolio management llc | 1,117,278 | $9.3M |
| oak hill advisors lp | 1,113,338 | $9.2M |
Showing top 10 of 190 institutional holders of Emergent BioSolutions Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 19.0%
- Days to cover
- 12.2
- Shares short
- 9,643,974
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EBS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Emergent BioSolutions Inc.?
Emergent BioSolutions Inc. is a public health company focused on medical countermeasures and NARCAN® Nasal Spray, with a portfolio of 11 products and a development pipeline addressing chemical, biological, radiological, nuclear, and emerging infectious disease threats.
What is Emergent BioSolutions Inc.'s lead drug candidate?
Emergent BioSolutions Inc.'s most advanced tracked candidate is anthrasil (Approved) for Treatment of inhalational anthrax.
What is Emergent BioSolutions Inc.'s next catalyst?
Emergent BioSolutions Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: TEMBEXA" — expected October 10, 2034.
Who is the CEO of Emergent BioSolutions Inc.?
Mr. Joseph C. Papa Jr., M.B.A., R.Ph. is the chief executive officer of Emergent BioSolutions Inc. (EBS).
Where is Emergent BioSolutions Inc. headquartered?
Emergent BioSolutions Inc. (EBS) is headquartered in Gaithersburg, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.